M. van Zonneveld Et Al. , "The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation," ALIMENTARY PHARMACOLOGY & THERAPEUTICS , vol.21, no.9, pp.1163-1171, 2005
van Zonneveld, M. Et Al. 2005. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. ALIMENTARY PHARMACOLOGY & THERAPEUTICS , vol.21, no.9 , 1163-1171.
van Zonneveld, M., Flink, H., Verhey, E., Senturk, H., Zeuzem, S., Akarca, U., ... Cakaloglu, Y.(2005). The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. ALIMENTARY PHARMACOLOGY & THERAPEUTICS , vol.21, no.9, 1163-1171.
van Zonneveld, M Et Al. "The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation," ALIMENTARY PHARMACOLOGY & THERAPEUTICS , vol.21, no.9, 1163-1171, 2005
van Zonneveld, M v. Et Al. "The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation." ALIMENTARY PHARMACOLOGY & THERAPEUTICS , vol.21, no.9, pp.1163-1171, 2005
van Zonneveld, M. Et Al. (2005) . "The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation." ALIMENTARY PHARMACOLOGY & THERAPEUTICS , vol.21, no.9, pp.1163-1171.
@article{article, author={M van Zonneveld Et Al. }, title={The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation}, journal={ALIMENTARY PHARMACOLOGY & THERAPEUTICS}, year=2005, pages={1163-1171} }